MacroGenics Inc (NASDAQ:MGNX)

3.02
Delayed Data
As of 3:59pm ET
 +0.01 / +0.33%
Today’s Change
2.13
Today|||52-Week Range
29.16
-81.18%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$204.9M

Company Description

MacroGenics, Inc. is a clinical-stage biopharmaceutical company engaged in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Contact Information

MacroGenics, Inc.
9704 Medical Center Drive
Rockville Maryland 20850-3368
P:(301) 251-5172
Investor Relations:

Employees

Shareholders

Other institutional53.40%
Mutual fund holders45.46%
Individual stakeholders26.16%

Top Executives

Scott E. KoenigPresident, Chief Executive Officer & Director
Eric RisserChief Operating Officer
James KarrelsChief Financial Officer, Secretary & Senior VP
Ezio BonviniChief Scientific Officer & Senior VP-Research
Stephen L. EckChief Medical Officer & SVP-Clinical Development